About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide

Massive Bio, a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC), a collaboration of several global biopharmaceutical companies, to optimize clinical trial matching through their innovative AI analytics tools. PCC was established in 2022 with a shared vision of enabling access to comprehensive testing for all cancer patients globally, and is currently comprised of AstraZeneca, Bayer, Eli Lilly & Company, GSK, Johnson & Johnson/Janssen, Novartis, and Roche. The partnership will incorporate PCC member clinical trial protocols and patient inclusion and exclusion criteria into existing machine learning matching algorithms in SYNERGY-AI leveraged within Massive Bio’s Deep Learning Clinical Trial Matching System (DLCTMS). This will optimize the quality and efficiency of matching patients to trials across sponsor programs and improve patient access to targeted Next Generation Sequencing (NGS) testing and tailored interventions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230602005015/en/

Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide (Graphic: Business Wire)

Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide (Graphic: Business Wire)

Selin Kurnaz PhD, Founder and CEO of Massive Bio, commented, "We are thrilled to be working with the Precision Cancer Consortium to advance precision oncology through our innovative AI analytics tools. With this partnership, we can streamline the process of clinical trial matching and reduce the burden on patients and healthcare systems."

The PCC is a collaborative initiative to make data-driven precision oncology the new normal for all cancer patients globally, focusing on increasing patient access to targeted NGS testing and tailored interventions. The program sponsored by PCC will generate combined data and insights to optimize the allocation of patients to available (“local”) clinical trials based on NGS testing or Comprehensive Genomic Profiling, clinical and patient characteristics, and relevant trial eligibility criteria.

Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer of Massive Bio, said, "We are proud to partner with the Precision Cancer Consortium and bring our AI analytics tools to the forefront of precision oncology. Our technology utilizes genomics and clinical data from various platforms to present available intervention options for each patient in order to optimize clinical trial matching by reducing inefficiencies and multiple screenings. Together, we can help more patients access the right treatment options and improve outcomes."

Through this partnership, Massive Bio will design and pilot a trial matching tool for prospectively matching patients through genomic testing and clinical data to a set of selected ongoing biomarker-driven clinical trials within previously defined locations (i.e. site, Health Care Organization, country). The companies will also explore considerations for larger scale or real-world application for further development.

Yinghui Zhou PhD, PCC Project Lead and Sr. Director, Bayer Translational Sciences Oncology, added, "This collaboration has the potential to address a major challenge in precision oncology and improve patient outcomes. By working together and utilizing a collection of genomics data from multiple sources centralized with the assistance of AI, we can create a valuable scientific resource and optimize the efficiency of clinical trial matching globally and scale."

About Precision Cancer Consortium (PCC)

The Precision Cancer Consortium is composed of pharmaceutical and biotechnology companies focused on fostering collaboration on issues and opportunities related to precision oncology with the goal of improving patient outcomes by increasing cancer patient access to comprehensive genomic testing, including next generation sequencing, and addressing major gaps in precision diagnostics availability.  For more information, visit the PCC website at https://www.precisioncancerconsortium.com/.

About Massive Bio

Massive Bio empowers cancer patients to find their best treatment options, using artificial intelligence to improve equitable access and precision targeting for clinical trial matching, drug matching, and drug development. Massive Bio combines its best-in-class AI platform with technology-enabled services to remove barriers in clinical trial enrollment, value-based oncology decisions, and data-driven cancer treatment. The company serves more than two dozen pharmaceutical companies, contract research organizations, and hospital networks, and has been awarded an SBIR contract by the National Cancer Institute. Massive Bio was founded in 2015 by clinical, technology, and M&A executives, and has a global presence with nearly 100 people in 12 countries. Follow @MassiveBio on social media.

 

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.